This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2013-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2020
Title: Akinori Imamura: Innovator in Protein Purification
Introduction
Akinori Imamura is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of protein purification, particularly in the development of methods for removing contaminants from antibody formulations. With a total of 3 patents to his name, Imamura's work is recognized for its impact on biopharmaceutical processes.
Latest Patents
Imamura's latest patents include a method for removing viruses in a physiologically-active protein-containing sample. This innovative approach involves manufacturing an antibody formulation by binding the antibody to a protein-A or protein-G affinity column and eluting the antibody with an acidic eluting solution, preferably of low conductivity. Another significant patent is his protein purification method, which shares similar principles in ensuring the removal of DNA contaminants from antibody formulations.
Career Highlights
Akinori Imamura is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. His work at Chugai has allowed him to focus on advancing techniques that enhance the safety and efficacy of therapeutic proteins.
Collaborations
Imamura has collaborated with esteemed colleagues such as Kozo Takeda and Manabu Matsuhashi. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of protein purification.
Conclusion
Akinori Imamura's contributions to the field of protein purification through his innovative patents highlight his role as a key inventor in the biopharmaceutical industry. His work continues to influence the development of safer and more effective therapeutic products.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
